Bloomberg Billionaires Index

View profiles for each of the world’s 500 richest people, see the biggest movers, and compare fortunes or track returns.

# Desh Gupta

Random fact: Gupta started his career as an associate professor.

Overview

Gupta was the chairman and major shareholder of Lupin, the world's sixth-largest generic pharmaceutical maker. The Mumbai-based company has 13 plants in India, Japan and Mexico, and sells its drugs in more than 100 countries. Publicly traded Lupin had revenue of about $2.5 billion in fiscal year 2017. Gupta died June 26, 2017.

As of Sept. 21, 2017:
Last change ()
YTD change ()
Industry Health Care
Biggest asset N/A
Citizenship India
Age 79
Wealth Self-made
View net worth over:   Max 1 year 1 quarter 1 month 1 week

Relative Value

Desh Gupta's net worth of can buy ...

0
troy ounces of gold
0
barrels of crude oil

... and is equivalent to ...

0%
of the GDP of the United States
0%
of the total wealth of the 500 richest people in the world
0%
of the top 100 U.S. college endowments
0%
of the top 200 U.S. executives’ total awarded compensation
0%
of U.S. existing home sales
0
times the median U.S. household income

Latest News

Net Worth Summary

Cash
Private asset
Public asset
Misc. liabilities
Confidence rating:

Biography

Birthdate: 2/8/1938
Family: Married, 5 children

Desh Bandhu Gupta started his career as an associate professor at the Birla Institute of Science and Technology in Rajasthan, India, after getting his masters degree in chemistry. He founded Lupin in 1968 to develop drugs to treat life-threatening diseases, borrowing about $80 from his wife, Manju Gupta, to fund the venture.

Lupin became the world's biggest maker of drugs to treat tuberculosis. Gupta turned to overseas markets as competition and government controls at home hurt earnings. He started selling branded products in the U.S. in 2004 after acquiring the antibiotic Suprax from Pfizer’s Wyeth unit, and expanded into Japan by buying a controlling stake in Kyowa Pharmaceutical Industry in 2007. Lupin made its foray into Latin America seven years later with the acquisition of Mexico's Laboratorios Grin.

Gupta's eldest daughter, Vinita, is the chief executive officer of Lupin and his son, Nilesh, is managing director and oversees manufacturing, regulatory filings and research.

Gupta died on the morning of June 26 in Mumbai, according to a statement on Lupin's website. His net worth had been $3.5 billion.

Milestones
  • 1968 Starts Lupin with about $80 borrowed from his wife.
  • 1988 Sets up Lupin Human Welfare & Research Foundation.
  • 2002 Lupin's patent filings surpass 100.
  • 2004 Starts selling branded drugs in the U.S. after buying the antibiotic Suprax.
  • 2006 Completes its first overseas convertible bond sale.
  • 2007 Buys Kyowa Pharmaceutical in Japan.
  • 2008 Acquires Germany's Hormosan Pharma.
  • 2013 Daughter Vinita becomes CEO of Lupin.
  • 2014 Makes foray into Latin America by acquiring Mexico's Laboratorios Grin.
  • 2016 Partnered with Eli Lilly to introduce a new diabetes treatment in India.